Jordan Keels

Ms. Jordan Keels

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2023 in Genes
Verified
Journal Article
Open access
PDF file
JTJoanne Thomas
Joanne Thomas
JKJordan Keels
Jordan Keels
KCKathleen Anne Calzone
Kathleen Anne Calzone
LBLaurie Badzek
Laurie Badzek
SDSarah Dewell
Sarah Dewell
Andrew A. DwyerAndrew A. Dwyer
Andrew A. Dwyer
In the 20 years since the initial sequencing of the human genome, genomics has become increasingly relevant to nursing. We sought to chart the current state of genomics in nursing by conducting a systematic scoping review of the literature in four databases (2012–2022). The included articles were categorized according to the Cochrane Collaboration outcome domains/sub-domains, and thematic analysis was employed to identify key topical areas to summarize the state of the science. Of 8532 retrieved articles, we identified 232 eligible articles. The articles primarily reported descriptive studies from the United States and other high-income countries (191/232, 82%). More than half (126/232, 54.3%) aligned with the “healthcare provider oriented outcomes” outcome domain. Three times as many articles related to the “knowledge and understanding” sub-domain compared to the “consultation process” subdomain (96 vs. 30). Five key areas of focus were identified, including “nursing practice” (50/126, 40%), “genetic counseling and screening” (29/126, 23%), “specialist nursing” (21/126, 17%), “nurse preparatory education” (17/126, 13%), and “pharmacogenomics” (9/126, 7%). Only 42/126 (33%) articles reported interventional studies. To further integrate genomics into nursing, study findings indicate there is a need to move beyond descriptive work on knowledge and understanding to focus on interventional studies and implementation of genomics into nursing practice.

28 January 2026 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
JKJordan Keels
Jordan Keels
RLRose D. LaPlante
Rose D. LaPlante
CLChristopher S. Lee
Christopher S. Lee
ADAndrew A. Dwyer
Andrew A. Dwyer
Aim: To estimate the prevalence of new‐onset diabetes in adults (≥ 18 years) following SARS‐CoV‐2 infection. Materials and Methods: This meta‐analysis includes studies written in English that measured the number of adults (≥ 18 years) diagnosed with diabetes following SARS‐CoV‐2 infection. Studies underwent dual independent review; quality was assessed by using the New Castle Ottawa Scale. A random‐effects meta‐analysis was conducted to obtain the pooled estimate of new‐onset diabetes. To understand the relationship between patient characteristics (age, sex) and study variable (duration of follow‐up), a random effects meta‐regression was used. Results: A total of 33 articles were retained for analysis. The overall estimated prevalence of new‐onset diabetes (combined T1DM and T2DM or undefined) was 8.33% (95% CI 7.47, 9.18%, z = 19.04, p < 0.001; Q = 6791.24, I 2 , 99.68%). The overall estimated prevalence of new‐onset T2DM in COVID‐19 was 8.92% (95% CI 7.88%, 9.96%, z = 16.77, p < 0.001; Q = 27659.74; p < 0.001, I 2 = 99.96%). The overall estimated prevalence of new‐onset T1DM was 0.86% (95% CI 0.0072%, 0.0099%, z = 12.59, p < 0.001; Q = 9456.28; p < 0.001, I 2 = 99.94%). At the study level, there was no significant relationship identified with age, sex, or follow‐up duration. Conclusions: This systematic review and meta‐analysis revealed a notable increase in T2DM or combined (T1DM, T2DM, or undefined) conditions. As such, it may be important to understand the underlying factors contributing to increased prevalence.

6 January 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
JKJordan Keels
Jordan Keels
IMIsabella R. McDonald
Isabella R. McDonald
CLChristopher S. Lee
Christopher S. Lee
ADAndrew A. Dwyer
Andrew A. Dwyer
Background: The effect of antidiabetic agents on mortality outcomes is unclear for individuals with diabetes mellitus (DM) who are hospitalized for COVID-19.Purpose: To examine the relationship between antidiabetic agent use and clinical outcomes in individuals with DM hospitalized for COVID-19.Methods: A systematic review of the literature (2020-2024) was performed across five databases. Included articles reported primary research (English) reporting clinical outcomes of adult patients (≥18 yrs.) with DM receiving antidiabetic agents who were hospitalized for COVID-19. Following PRISMA guidelines articles underwent independent dual review. Quality appraisal was completed for included studies. Independent reviewers used a structured data extraction form to retrieve relevant data. Aggregated data were synthesized by treatment regimen and reported descriptively. Random effects meta-analyses were performed to assess relative risk and prevalence of mortality.Results: After removing duplicates, title and abstract screening of 4,898 articles identified 118 articles for full-text review and 35 articles were retained for analysis. Included articles were primarily from China (15/35, 43%) and retrospective in nature (31/35, 89%). Fourteen studies (40%) assessed multiple antidiabetic agents, fifteen studies (42%) focused on metformin, three studies (9%) assessed the use of DPP-4 inhibitors, and three single studies (9%) investigated the use of insulin, TZD, and SGLT2 inhibitors. Despite differences among studies, the overall relative risk of mortality among metformin and DPP-4 inhibitor users was 0.432 (95% CI = 0.268-0.695, z = 3.45, p < 0.001) and the overall prevalence of mortality among all antidiabetic users was 16% (95% CI = 13%–19%, z = 10.70, p < 0.001).Conclusions and implications: Synthesis of findings suggest that patients who remained on oral agents (with/without supplemental insulin therapy) exhibited decreased mortality and lower inflammatory markers. Results indicate that individuals with DM should continue oral antidiabetic agents with additional basal insulin as needed to improve glycemic control and reduce mortality. Further work is needed to uncover mechanism(s) and clarify medical management approaches.

22 May 2025 in Genes
Verified
Journal Article
Open access
PDF file
SSSamantha Strasser
Samantha Strasser
IMIsabella McDonald
Isabella McDonald
MUMelissa K Uveges
Melissa K Uveges
Sharlene Hesse-BiberSharlene Hesse-Biber
Sharlene Hesse-Biber
JKJordan Keels
Jordan Keels
Andrew A. DwyerAndrew A. Dwyer
Andrew A. Dwyer
Background/Objectives: Rare diseases are predominantly genetic in etiology and characterized by a prolonged ‘diagnostic odyssey’. Advances in genetic testing (GT) have helped shorten the time to diagnosis for rare/undiagnosed conditions. We aimed to synthesize the evidence on psychosocial factors related to GT for rare diseases to inform more person-centered approaches to care. Methods: We conducted a systematic literature search in six databases using structured terms (September 2024). Retrieved articles underwent independent dual review. Data were extracted and collated in tables for analysis. Thematic analysis was used to identify promoters/barriers to GT for patients and families. Findings were validated by a patient advocate and were reported using PRISMA-ScR guidelines. Synthesized findings were mapped to the Theory of Planned Behavior to inform intervention development. Results: Of 1730 retrieved articles, 32 were included for data extraction/synthesis. Studies employed qualitative (n = 19), quantitative (n = 10), and mixed-methods (n = 3) approaches. Nearly all (29/32, 91%) were non-interventional, reporting on decision-making cognitions/processes (19/32, 59%), attitudes/preferences (15/32, 47%), psychosocial impact (6/32, 19%), and knowledge/awareness (4/32, 8%) of pre-conception/prenatal/diagnostic GT and carrier screening. Promoters included understanding GT, ending the diagnostic odyssey, actionable outcomes, personal/family history, altruism, and reproductive decision-making. Barriers included logistical (e.g., distance, cost), psychological burden, perceived lack of benefit, and discrimination/social stigma concerns. Conclusions: Some psychosocial factors related to GT for rare diseases overlap with those in literature on GT for common conditions. Identified factors represent targets for theory-informed, person-centered interventions to support high-quality GT decisions that are informed and aligned with patient/family values and preferences.

9 July 2026 in International Nursing Review
Verified
Journal Article
Open access
JKJordan Keels
Jordan Keels
JTJoanne Thomas
Joanne Thomas
KCKathleen Anne Calzone
Kathleen Anne Calzone
LBLaurie Badzek
Laurie Badzek
SDSarah Dewell
Sarah Dewell
Andrew A. DwyerAndrew A. Dwyer
Andrew A. Dwyer
Aim: This study aimed to summarize the current state of the science for “health service delivery–oriented outcomes” from nursing in genomics (2012–2025). Background: Nurses can play a vital role in increasing access to genomic healthcare and improving outcomes for patients, families, and communities. Methods: We conducted a scoping review of the literature in four databases (2012–2025). Articles were categorized using the Cochrane Collaboration outcome domains and sub‐domains to identify salient topics and synthesize findings. Results: Of 11,646 retrieved articles, 66 publications reporting “health service delivery–oriented outcomes” were included for analysis. Identified articles spanned three sub‐domains: “service delivery level,” “related to research,” and “societal or governmental.” Within sub‐domains, articles were further categorized into dimensions, the most prominent being “service utilization” under the “service delivery level” sub‐domain. Studies were primarily from anglophone countries and near‐evenly split into interventional and noninterventional studies. Studies reported that nurses working in multidisciplinary and/or interprofessional teams are a cost‐effective means to increase access to genomic healthcare and reduce burden on genetic specialists. Nurses are incorporating genomics in various settings, including oncology, pharmacogenomics, genetic counseling, rare genetic diseases, and symptom science. Conclusion: Despite evidence of nurses contributing to health system delivery‐oriented outcomes, evidence suggests that nurses are underutilized and underprepared in genomic healthcare. Implications for Nursing: A significant barrier to integrating genomics into nursing practice is a lack of foundational knowledge and genomic competency across nursing education, clinical practice, and nursing policymakers. Implications for Nursing Policy: Nursing leadership spanning education, research, practice, and policy domains will be critical for integrating genomics in nursing practice and improving health system delivery‐oriented outcomes.

25 April 2026 in Cancers
Verified
Journal Article
Open access
PDF file
JKJordan Keels
Jordan Keels
VBViktoriya Babicheva
Viktoriya Babicheva
IMIsabella R. McDonald
Isabella R. McDonald
JWJessica K. Witt
Jessica K. Witt
Andrew A. DwyerAndrew A. Dwyer
Andrew A. Dwyer
Background/Objectives: We aimed to test two different visual arrays for helping individuals accurately interpret colorectal cancer risk in Lynch syndrome. We also sought to examine factors associated with intention to share genetic test results with blood relatives. Methods: Participants were recruited through Amazon Mechanical Turk (July–August 2025). Participants completed an online REDCap survey evaluating genetic literacy/numeracy and risk perception (Tripartite Model of Risk Perception). Participants were randomized to a risk visualization—either a standard icon array or a sequential icon array intended to decrease cognitive load. Subsequently, participants were randomized to a communication choice scenario—a nondirective (choice) frame or an “enhanced choice” with a behavioral nudge based on the Theory of Planned Behavior. Results: Participants’ (n = 1041) estimation of colorectal cancer risk did not differ according to visualization type (icon array: 60.36 ± 15.86%, sequential array: 60.91 ± 15.73%, p = 0.58). Intention to share genetic testing outcomes with family members was not influenced by the behavioral nudge (p = 0.23). Neither risk estimation nor intent to communicate results to blood relatives were affected by individual perceived colorectal cancer risk, health literacy/numeracy, education, previous genetic testing, personal cancer history, or family cancer history (all p > 0.11 and p > 0.21, respectively). Conclusions: This study found that visual array type did not affect estimated cancer risk, and decision frame did not affect intention to share genetic testing results. Findings could inform the development of online approaches to expand decision support for hereditary cancer syndromes (Clinicaltrials.gov #NCT06994832).